INTRODUCTION
Vitamin D, through its active form, 1,25-dihydroxyvitamin D [1, 25(OH) 2 D], is essential for intestinal calcium absorption and plays a central role in maintaining calcium homeostasis and skeletal integrity (1) . In addition to these classical actions, 1,25(OH) 2 D also has nonclassical actions unrelated to calcium metabolism, including regulation of cell differentiation and proliferation, cellular growth, and hormone secretion (2) . Optimal vitamin D status is important to human health, and there is a consensus that serum or plasma 25- (1), but there is a lack of consensus on the cutoff that defines the lower limit of adequacy or sufficiency, with suggested values between 30 and 80 nmol/L (4, 7, 8) .
Severe clinical vitamin D deficiency [serum/plasma 25(OH)D ,10-25 nmol/L] leads to rickets in children and osteomalacia in adults (1) . Less severe deficiency causes secondary hyperparathyroidism and increases bone turnover and bone loss (9) (10) (11) . In addition, serum 25(OH)D ,50 nmol/L may be associated with increased risk of nonskeletal chronic diseases (2, 12) . Some, but not all (13, 14) , studies suggest that supplementation with vitamin D 3 (cholecalciferol) and vitamin D 2 (ergocalciferol) appears to possess equal bioavailability (15, 16) (17, 18) . In terms of safety, the European Food Safety Authority (19) and the US Dietary Reference Intake panel on calcium and related nutrients have set 50 lg vitamin D/d as the Tolerable Upper Intake (4) .
In recent years, investigators have proposed use of biomarkers or functional endpoints, eg, parathyroid hormone (PTH), calcium absorption, bone resorption, and bone mineral density (BMD), to more clearly define adequacy of circulating 25(OH)D concentrations with respect to calcium homeostasis (20) (21) (22) (23) . It has been suggested that 25(OH)D alone is inadequate to define dietary requirements for vitamin D because optimal concentrations for health are unknown, so dietary requirements should be on the basis of functional outcome measures (21) . Because optimal vitamin D intake is influenced by calcium intake and vice versa, Weaver and Fleet (21) suggest that this interdependence must be taken into account.
Thus, the aim of this systematic review was to assess the usefulness of existing and novel functional markers of vitamin D status in healthy humans, which may be of use in defining dietary requirements. Where the evidence allowed, we also explored the effect of vitamin D-calcium interdependencies on the usefulness of such markers.
METHODS
The methodology follows the general methodology for reviews in this supplement (24) , with brief specific details as follows.
Inclusion criteria
Studies were randomized controlled trials (RCTs) of vitamin D (with or without calcium) supplementation in apparently healthy humans that fulfilled all of the following characteristics: 1) vitamin D 3 or D 2 50 lg/d (2000 IU, 1 lg ¼ 40 IU) administered orally alone or with calcium; 2) reported serum or plasma 25(OH)D after supplementation in at least one intervention group and one control group; 3) no other coadministered nutrients (besides calcium), hormones, or pharmaceutical agents; and 4) 6-wk minimum duration. To assess calcium absorption, these criteria were relaxed (as otherwise there were insufficient studies). These studies did not have to be RCTs or !6-wk duration.
Search strategy
Electronicsearcheswererun[onOvidMEDLINE,EMBASE(Ovid; www.ovid.com), and Cochrane CENTRAL (www.thecochranelibrary. com) from inception to 25 September 2007 by using a structured search strategy in the following format: [(vitamin D supplements) AND (supplementation or depletion studies in humans)] (see Table S1 under ''Supplemental data'' in the online issue for the full Ovid MEDLINE search strategy). A vitamin D expert was contacted, reference lists of 10 reviews were drawn from electronic searches of reviews run on Ovid MEDLINE (2, 7, (20) (21) (22) (23) (25) (26) (27) (28) , and all of the included studies were checked and additional articles collected and assessed for inclusion.
Data collection
Screening of titles and abstracts for collection, screening fulltext articles for inclusion, and data extraction (eg, quality assessment) from included studies all were performed by a single reviewer with independent duplicate assessment of 100% by a second reviewer.
Data synthesis
A flowchart showing the number of studies assessed and included in the review is shown in Figure 1 . We extracted the number of participants included (and assessed) in each arm of each RCT plus means and SDs of the baseline and change in each vitamin D status biomarker (from baseline to each assessed time point) in the control and intervention arms or means and SDs of the baseline and final values in the treatment and control arms at each time point and for each vitamin D dose. For beforeafter studies, baseline and later readings in the intervention group at each time point and for each vitamin D dose were used.
In cases in which there were !2 intervention arms and 1 common control group, only the highest dose of supplement ,2000 IU/d and the control arm were used for the primary analysis. For subgrouping (eg, by dose), the various arms compared with control were included as long as the arms fell into different dose range subgroups. In cases in which data were presented for 2 groups separately (eg, data for men and women presented separately), these were treated as 2 studies in the analysis.
RESULTS
In total, 2363 titles and abstracts were screened ( Figure 1 ), and 40 studies (36 RCTs and 4 before-after studies) were included (11, 17, 18, . Of the 36 RCTs, 32 provided extractable data on serum or plasma 25(OH)D data, 16 on serum/plasma PTH data, 6 on bone turnover marker data, and 6 on BMD data. Four before-after studies were included for investigation of calcium absorption.
Details of included studies (including some criteria of quality) are shown in Table 1 . Of the 40 studies, 7 were in men and 25 in women (the remainder were mixed). Of the RCTs, 2 studies were in infants, 4 in children and adolescents, 6 in adults, 9 in elderly, and 15 in postmenopausal women (some studies had more than one population subgroup). Most studies (n ¼ 32) Of the 36 RCTs, all had similar vitamin D status marker concentrations in intervention and control arms at baseline, with a wide range of participants per study arm (9-466 subjects). The studies were of adequate duration to reflect a change in vitamin D status. Only 25% and 38% of studies reported verification of the supplementation dose and reported compliance, respectively. There was a wide range in percentage of subject dropout (0-32% within a study arm) in these studies. In general, with the exception of the latter limitations, the included studies were of reasonable validity ( Table 2) .
Circulating 25(OH)D
The primary analysis was highly heterogeneous, but point estimates for all but one RCT (35) showed a statistically Table 4 . There is good evidence that circulating PTH is an effective marker of vitamin D status in postmenopausal women and the elderly but not in other adults (with insufficient evidence to assess in the infants or children/ adolescents groups) and with no suggestion of effectiveness in either group and no available evidence during pregnancy and lactation or in low-income and immigrant groups. Circulating PTH appears to work as a marker in men and women (although the women's studies are primarily the postmenopausal studies) and at high doses of vitamin D (401-2000 IU/d) but not clearly at lower doses.
4%). Further subgrouping is shown in
Metaregression of vitamin D dose compared with serum or plasma PTH concentration suggested a lack of statistically significant association (regression coefficient b: 20.0004 pmol/L; SE: 0.0003; P ¼ 0.304) (data not shown).
Bone turnover markers and BMD
Six RCTs assessed the effect of vitamin D supplementation on serum osteocalcin, 3 on serum bone-specific alkaline phosphatase, 2 each on serum C-terminal telopeptide of type I collagen and urinary cross-linked N-telopeptides of type I collagen, and 4 on urinary deoxypyridinoline. There was no suggestion that any of these was a useful marker of vitamin D status (Table 5) , although there were too few studies assessing urinary cross-linked N-telopeptides of type I collagen or serum C-terminal telopeptide of type I collagen to be sure. There were too few studies to carry out further subgrouping.
Six RCTs reported on the effect of vitamin D supplementation on BMD, 3 on BMD at the lumbar spine, 3 at the femoral neck, and 3 on the whole body (several studies assessed BMD at more than one site). None of the individual sites (including whole-body BMD) was statistically significant in its own right ( Figure 5 ). There was a suggestion that BMD may be a useful marker in older people but not in adolescents. When analysis was limited to the 2 studies in older subjects (30, 40) , supplementation increased whole-body BMD significantly and with no heterogeneity (WMD: 0.10%; 95% CI: 0.03, 0.17; 2 studies; 492 participants; I 2 ¼ 0%) and increased lumbar spine BMD (40, 61) significantly and with no heterogeneity (WMD: 0.82%; 95% CI: 0.60, 0.83; 2 studies; 442 participants; I 2 ¼ 0%).
Intestinal calcium absorption
Pooling 4 before-after studies that investigated effects of vitamin D [3 used 25(OH)D as the supplemental form of vitamin D] on intestinal calcium absorption showed high levels of heterogeneity but suggested a statistically significant result (random effects: 13.5%; 95% CI: 3.7, 23.3; 4 studies; 112 participants; I 2 ¼ 67.8%) ( Figure 6 ).
DISCUSSION
Many analyses suffer from high levels of heterogeneity, but this is not unexpected because the included RCTs had variable population groups, doses, and supplementation form (vitamin D 2 (15, 16) . Although choice of measurement methodology can influence the absolute quantification of circulating concentrations of 25(OH)D, and this has been comprehensively discussed elsewhere (26, 66) , international quality-assurance schemes, eg, DEQAS (66) and emerging standard reference materials for 25(OH)D, can and will further help limit interlaboratory assay-specific differences in this status marker. That duration of study (.6 wk as defined by our inclusion criteria) did not influence the response of circulating 25(OH)D to supplemental vitamin D also was expected because serum 25(OH)D concentrations have been shown to reach equilibrium after 6-8 wk of vitamin D supplementation in adult and elderly subjects (17, 18) .
In relation to the interesting concept of vitamin D-calcium interdependencies (21) , which might affect the usefulness of status markers for both nutrients, our analysis suggested that the response of circulating 25(OH)D to supplemental vitamin D was similar whether or not calcium was coadministered. Some have argued that a high dietary calcium intake has a sparing effect on serum 25(OH)D because PTH concentrations will be suppressed, thus less serum 25(OH)D converted to 1,25(OH) 2 D 3 (7) . This issue may require a more direct approach in terms of study design to be answered adequately.
The ultimate effect of vitamin D on human health is primarily maintenance of calcium homeostasis and a healthy skeleton, although other noncalcemic health effects have been suggested (2, 12) . Interestingly, the US Dietary Reference Intake panel for calcium and related nutrients suggested that, in relation to establishing Adequate Intakes for vitamin D, one of the indicators that has proved valuable is an evaluation of skeletal health (4). For example in adults, the panel suggested that bone mineral content, resorption by biochemical markers is subject to limitations associated with these markers, in particular the high intersubject variability (67) . Weaver and Fleet (21) suggested that for such vitamin D-bone resorption studies, bone resorption should be assessed by more sensitive approaches, such as in calcium tracer kinetic studies and studies that use the novel semistable 41 Ca radioisotope. Unfortunately, vitamin D supplementation studies thus far have not used these techniques; therefore, we should remain open to the possible usefulness of bone resorption as a functional marker of vitamin D status while awaiting muchneeded experimental data.
In the current study, BMD of some but not other skeletal sites responded to vitamin D supplementation. BMD of whole body and lumbar spine significantly responded to vitamin D supplementation only when analysis was limited to 2 studies in older subjects. On the other hand, BMD of the femoral neck did not significantly respond to vitamin D supplementation. Aside from the fact that only 2 studies of older subjects were available for inclusion, all of the other a priori criteria (24) to claim BMD (at selected sites) was effective as a marker were met.
The current analysis suggested that intestinal calcium absorption responded to vitamin D supplementation [albeit with 25(OH)D] and may be a novel functional status marker for vitamin D, as proposed by some (20) (21) (22) (23) . When analysis was limited to 3 studies in older subjects, all of the a priori criteria (24) to claim calcium absorption was effective as a marker were met.
In conclusion, although the current systematic review of various existing and potentially novel markers of vitamin D status was hinderedbylimitationsoftheselectedRCTs[asdiscussedbyHooper et al (24) ], all of which contributed to the heterogeneity, it provided some interesting evidence to suggest that the more novel functional markers of vitamin D status (eg, BMD and intestinal calcium absorption) are worthy of further investigation. This should include more appropriately designed studies (addressing some of the quality issues and limitations highlighted in this review) in a variety of population subgroups, which also can test the affect of vitamin D-calcium interdependencies on the usefulness of such markers. In the meantime, the current analysis provides further confidence in the use of serum 25(OH)D and, to a much more limited extent, serum PTH as the status markers of vitamin D. There also is a need for systematic reviews of diagnostic accuracy on these more novel markers of vitamin D assessment [to compare these markers to serum or plasma 25(OH)D]. (Other articles in this supplement to the Journal include references 24 and 68-74.) 
